KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Gross Margin: 2020-2024

Historic Gross Margin for Esperion Therapeutics (ESPR) over the last 5 years, with Dec 2024 value amounting to 79.36%.

  • Esperion Therapeutics' Gross Margin fell 1381.00% to 52.71% in Q3 2025 from the same period last year, while for Sep 2025 it was 58.20%, marking a year-over-year decrease of 2338.00%. This contributed to the annual value of 79.36% for FY2024, which is 1655.00% up from last year.
  • As of FY2024, Esperion Therapeutics' Gross Margin stood at 79.36%, which was up 26.35% from 62.81% recorded in FY2023.
  • Esperion Therapeutics' Gross Margin's 5-year high stood at 98.95% during FY2020, with a 5-year trough of 62.81% in FY2023.
  • In the last 3 years, Esperion Therapeutics' Gross Margin had a median value of 64.27% in 2022 and averaged 68.81%.
  • In the last 5 years, Esperion Therapeutics' Gross Margin plummeted by 1,761bps in 2022 and then spiked by 1,655bps in 2024.
  • Esperion Therapeutics' Gross Margin (Yearly) stood at 98.95% in 2020, then plummeted by 1,707bps to 81.88% in 2021, then plummeted by 1,761bps to 64.27% in 2022, then slumped by 146bps to 62.81% in 2023, then surged by 1,655bps to 79.36% in 2024.